Pharmacokinetic and Safety Comparison of Fixed‐Dose Combination of Cilostazol/Rosuvastatin (200 + 20 mg) Versus Concurrent Administration of the Separate Components in Healthy Adults
Clinical Pharmacology in Drug Development · 2024-08 · 13 (8) · 842-851
DOI: 10.1002/cpdd.1390 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 12.03.2024. Verfasst von Jae Hoon Kim und 12 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trials Center, Chungnam National University Hospital, Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Rosuvastatin Calcium, Cilostazol, Cross-Over Studies, Drug Combinations. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
The combined cilostazol and rosuvastatin therapy is frequently used for coronary artery disease treatment. This open‐label, 3 × 3 crossover clinical trial evaluated the pharmacokinetics and safety of a fixed‐dose combination (FDC) of cilostazol/rosuvastatin (200 + 20 mg) versus a concurrent administration of the separate components (SCs) under both fasted and fed conditions. Among 48 enrolled healthy adults, 38 completed the study. Participants were administered a single oral dose of cilostazol/rosuvastatin (200 + 20 mg), either as an FDC or SCs in a fasted state, or FDC in a fed state, in each period of the trial. Blood samples were taken up to 48 hours after dosing, and plasma concentrations were analyzed using validated liquid chromatography‐tandem mass spectrometry. The geometric mean ratios of FDC to SCs for area under the plasma concentration‐time curve from time zero to the last quantifiable concentration (AUC last ) and maximum plasma concentration (C max ) were 0.94/1.05 and 1.06/1.15 for cilostazol and rosuvastatin, respectively (AUC last /C max ). Compared with that during fasting, fed‐state administration increased the AUC last and C max for cilostazol by approximately 72% and 160% and decreased these parameters for rosuvastatin by approximately 39% and 43%, respectively. To conclude, the FDC is bioequivalent to the SCs, with notable differences in pharmacokinetics when administered in a fed state. No significant safety differences were observed between the treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Trials Center, Chungnam National University Hospital, Daejeon, Republic of Korea.
- Department of Medical Science, Chungnam National University College of Medicine, Daejeon, Republic of Korea.
- Department of Pharmacology, Chungnam National University College of Medicine, Daejeon, Republic of Korea.
- Department of Family Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea.
- Korea United Pharmaceutical Corporation, Seoul, Republic of Korea.
- Caleb Multilab Corporation, Seoul, Republic of Korea.
Zitieren
APA
Kim, J. H., Hong, J. H., Jung, J. G., Jung, W. T., Nam, K. Y., Roh, J. S., Choi, Y. W., Bang, J., Huh, H., Lee, H. J., Moon, J., Kim, J., & Sunwoo, J. (2024). Pharmacokinetic and Safety Comparison of Fixed‐Dose Combination of Cilostazol/Rosuvastatin (200 + 20 mg) Versus Concurrent Administration of the Separate Components in Healthy Adults. Clinical Pharmacology in Drug Development, 13(8), 842-851. https://doi.org/10.1002/cpdd.1390
Vancouver
Kim JH, Hong JH, Jung JG, Jung WT, Nam KY, Roh JS, et al. Pharmacokinetic and Safety Comparison of Fixed‐Dose Combination of Cilostazol/Rosuvastatin (200 + 20 mg) Versus Concurrent Administration of the Separate Components in Healthy Adults. Clinical Pharmacology in Drug Development. 2024;13(8):842-851. doi:10.1002/cpdd.1390
BibTeX
@article{Kim2024,
author = {Kim, Jae Hoon and Hong, Jang Hee and Jung, Jin-Gyu and Jung, Won Tae and Nam, Kyu-Yeol and Roh, Jae Seok and Choi, Youn Woong and Bang, Junbae and Huh, Hyunwook and Lee, Hye J and Moon, JungHa and Kim, Jaehee and Sunwoo, Jung},
title = {Pharmacokinetic and Safety Comparison of Fixed‐Dose Combination of Cilostazol/Rosuvastatin (200 + 20 mg) Versus Concurrent Administration of the Separate Components in Healthy Adults},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
volume = {13},
number = {8},
pages = {842--851},
doi = {10.1002/cpdd.1390}
}
EUVIMED